Home › Macular Degeneration › NCT07798323

Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.

Who can join

Ages 50 to 80 · All sexes

Inclusion Criteria:

* 50-80 years of age
* All genders
* Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes
* Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio

Exclusion Criteria:

* Poor image quality that limits quantification
* GA extending beyond the borders of the SDOCT field of view.
* Bilateral symmetric geographic atrophy.
* Diagnosis of wet AMD.
* Any retinal fluid at baseline.
* Other concurrent retinal diseases
* Vitreoretinal surgery.
* Allergy to iodinated contrast agents.
* Chronic kidney disease with eGFR \< 60

About the study

The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).

Sponsor: Scott Raymond · Participants: 30 · Started: Sep 1, 2026

Contact the study team

• Sara Lautzenhiser Research Coordinator · Phone: 216-444-3026

Official record on ClinicalTrials.gov — NCT07798323

Locations in the U.S.

Conditions

• Macular Degeneration

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.